Date:3/9/2010

rm use of Reglan and generic forms of metoclopramide has been linked to Tardive Dyskinesia, a serious involuntary and repetitive movement disorder that is often irreversible. A recent study cited by the FDA, reports the prevalence of Tardive Dyskinesia at 20 percent among patients treated with Reglan for at least 12 weeks. In February 2009, the FDA issued a Black Box warning against continued use of Reglan to treat gastrointestinal disorders.

ReglanJustice.com is meant to provide consumers with the critical information denied to them by the pharmaceutical manufacturers marketing these drugs.  For those consumers who have already been disabled by these products, ReglanJustice.com provides an avenue to seek legal redress.  Corporations that operate with an eye on the bottom line rather than the safety of their consumers must be held accountable for their actions.  For more information, visit www.reglanjustice.com.

"As attorneys, we've seen first hand the damage that can be done by these powerful and dangerous drugs," said Scott Nabers, partner at Blizzard, McCarthy & Nabers.  "Consumers were misinformed about the risks associated with this product and many have been permanently disabled.  It is our hope that this website will provide consumers with
'/>"/>

SOURCE Blizzard, McCarthy & Nabers, LLP Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
2. Neurocrine Biosciences to Present at the 30th Annual Cowen & Co. Health Care Conference
3. P&M Corporate Finance and Robin Young Announce 2010 Spine Technology Summit
4. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
5. TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers
6. UBM Announces Plans for Japan Pharma & Bio Events
7. Frost & Sullivan Recognizes Timoptic(R) (timolol maleate) as Best Brand Name Beta Blocker for Glaucoma: Timoptic Brand is Highest Rated in Survey of Ophthalmologists
8. Rapid Review Imaging System From P&R Dental Strategies Assures Fast, Accurate and Efficient Dental Claim Review
9. China Biologic Products to Present at the Rodman & Renshaw Annual China Investment Conference
10. Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
11. Aurora Womens Pavilion Center for Sexual Health & Wellness Receives Grant to Treat Vulvar Pain